Xingjuan Chao Sells 6,030 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 6,030 shares of CeriBell stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $108,540.00. Following the completion of the transaction, the chief executive officer owned 830,317 shares of the company’s stock, valued at $14,945,706. This trade represents a 0.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $20.10, for a total transaction of $783,900.00.
• On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.40, for a total transaction of $717,600.00.
• On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $17.45, for a total transaction of $680,550.00.

CeriBell Price Performance

Shares of NASDAQ:CBLL traded up $0.03 during trading on Tuesday, reaching $18.80. The stock had a trading volume of 187,155 shares, compared to its average volume of 322,889. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $24.33. The business’s 50-day moving average price is $19.08 and its 200 day moving average price is $19.19. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01. The stock has a market capitalization of $713.27 million, a PE ratio of -11.53 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The firm had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. As a group, equities analysts predict that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Institutional Trading of CeriBell

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after acquiring an additional 147,013 shares during the period. KCM Capital Inc grew its holdings in CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after acquiring an additional 400,000 shares during the period. Yu Fan grew its holdings in CeriBell by 10.7% during the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after acquiring an additional 130,964 shares during the period. Bank of New York Mellon Corp grew its holdings in CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after acquiring an additional 1,162,200 shares during the period. Finally, Novo Holdings A S grew its holdings in CeriBell by 2.3% during the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after acquiring an additional 20,000 shares during the period.

Analysts Set New Price Targets

Several research firms recently weighed in on CBLL. Canaccord Genuity Group dropped their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. Finally, BTIG Research restated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.